Chronic alcohol consumption causes alcohol-induced lipogenesis and promotes hepatic injury by preventing the oxidation of hepatocellular
fatty acids through the suppression of the activation of
AMP-activated protein kinase (AMPK).
HIMH0021, an active
flavonoid compound, which is a component of the Acer tegmentosum extract, has been shown to protect against liver damage caused by alcohol consumption. Therefore, in this study, we aimed to determine whether
HIMH0021 could regulate
alcoholic fatty liver and liver injury in mice.
Oral administration of 10 days of Lieber-DeCarli
ethanol plus a single binge of 30%
ethanol (chronic-plus-binge model) induced steatosis and liver injury and
inflammation in mice, which appears similar to the condition observed in human patients with alcohol-related diseases.
HIMH0021, which was isolated from the active
methanol extract of A. tegmentosum, inhibited alcohol-induced steatosis and attenuated the serum levels of
alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) during hepatocellular alcohol metabolism, both of which promote lipogenesis as well as liver
inflammation. Treatment with
HIMH0021 conferred protection against lipogenesis and liver injury, inhibited the expression of
cytochrome P4502E1, and increased serum
adiponectin levels in the mice subjected to chronic-plus-binge feeding. Furthermore, in hepatocytes,
HIMH0021 activated
fatty acid oxidation by activating pAMPK, which comprises pACC and CPT1a. These findings suggested that
HIMH0021 could be used to target a TNFα-related pathway for treating patients with
alcoholic hepatitis.